PMID- 37349704
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20240425
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Print)
IS  - 1465-9921 (Linking)
VI  - 24
IP  - 1
DP  - 2023 Jun 22
TI  - Plasma matrix metalloproteinase-3 predicts mortality in acute respiratory 
      distress syndrome: a biomarker analysis of a randomized controlled trial.
PG  - 166
LID - 10.1186/s12931-023-02476-5 [doi]
LID - 166
AB  - BACKGROUND: Matrix metalloproteinase-3 (MMP-3) is a proteolytic enzyme involved 
      in acute respiratory distress syndrome (ARDS) pathophysiology that may serve as a 
      lung-specific biomarker in ARDS. METHODS: This study was a secondary biomarker 
      analysis of a subset of Albuterol for the Treatment of Acute Lung Injury (ALTA) 
      trial patients to determine the prognostic value of MMP-3. Plasma sample MMP-3 
      was measured by enzyme-linked immunosorbent assay. The primary outcome was the 
      area under the receiver operating characteristic (AUROC) of MMP-3 at day 3 for 
      the prediction of 90-day mortality. RESULTS: A total of 100 unique patient 
      samples were evaluated and the AUROC analysis of day three MMP-3 showed an AUROC 
      of 0.77 for the prediction of 90-day mortality (95% confidence interval: 
      0.67-0.87), corresponding to a sensitivity of 92% and specificity of 63% and an 
      optimal cutoff value of 18.4 ng/mL. Patients in the high MMP-3 group 
      (>/= 18.4 ng/mL) showed higher mortality compared to the non-elevated MMP-3 group 
      (< 18.4 ng/mL) (47% vs. 4%, p < 0.001). A positive difference in day zero and day 
      three MMP-3 concentration was predictive of mortality with an AUROC of 0.74 
      correlating to 73% sensitivity, 81% specificity, and an optimal cutoff value 
      of + 9.5 ng/mL. CONCLUSIONS: Day three MMP-3 concentration and difference in day 
      zero and three MMP-3 concentrations demonstrated acceptable AUROCs for predicting 
      90-day mortality with a cut-point of 18.4 ng/mL and + 9.5 ng/mL, respectively. 
      These results suggest a prognostic role of MMP-3 in ARDS.
CI  - (c) 2023. The Author(s).
FAU - Jones, Timothy W
AU  - Jones TW
AD  - Department of Pharmacy, Augusta University Medical Center, 1120 15th St., 
      Augusta, GA, 30912, USA. tijones1@augusta.edu.
AD  - Department of Clinical and Administrative Pharmacy, University of Georgia College 
      of Pharmacy, 120 15th Street, HM-117, Augusta, GA, 30912, USA. 
      tijones1@augusta.edu.
FAU - Almuntashiri, Sultan
AU  - Almuntashiri S
AD  - Department of Clinical and Administrative Pharmacy, University of Georgia College 
      of Pharmacy, 120 15th Street, HM-117, Augusta, GA, 30912, USA.
FAU - Chase, Aaron
AU  - Chase A
AD  - Department of Pharmacy, Augusta University Medical Center, 1120 15th St., 
      Augusta, GA, 30912, USA.
AD  - Department of Clinical and Administrative Pharmacy, University of Georgia College 
      of Pharmacy, 120 15th Street, HM-117, Augusta, GA, 30912, USA.
FAU - Alhumaid, Abdullah
AU  - Alhumaid A
AD  - Department of Clinical and Administrative Pharmacy, University of Georgia College 
      of Pharmacy, 120 15th Street, HM-117, Augusta, GA, 30912, USA.
FAU - Somanath, Payaningal R
AU  - Somanath PR
AD  - Department of Clinical and Administrative Pharmacy, University of Georgia College 
      of Pharmacy, 120 15th Street, HM-117, Augusta, GA, 30912, USA.
FAU - Sikora, Andrea
AU  - Sikora A
AD  - Department of Clinical and Administrative Pharmacy, University of Georgia College 
      of Pharmacy, 120 15th Street, HM-117, Augusta, GA, 30912, USA.
FAU - Zhang, Duo
AU  - Zhang D
AD  - Department of Clinical and Administrative Pharmacy, University of Georgia College 
      of Pharmacy, 120 15th Street, HM-117, Augusta, GA, 30912, USA.
LA  - eng
GR  - TL1 TR002382/TR/NCATS NIH HHS/United States
GR  - UL1 TR002378/TR/NCATS NIH HHS/United States
GR  - R00HL141685/NH/NIH HHS/United States
GR  - UL1TR002378/NH/NIH HHS/United States
PT  - Letter
PT  - Randomized Controlled Trial
DEP - 20230622
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Matrix Metalloproteinase 3
MH  - *Respiratory Distress Syndrome
MH  - Lung
MH  - Prognosis
MH  - Biomarkers
PMC - PMC10286483
OTO - NOTNLM
OT  - Acute lung injury
OT  - Acute respiratory distress syndrome
OT  - Biomarker
OT  - Matrix metalloproteinase-3
OT  - Mortality prediction
COIS- The authors declare that they have no competing interests.
EDAT- 2023/06/23 01:10
MHDA- 2023/06/26 06:41
PMCR- 2023/06/22
CRDT- 2023/06/22 23:36
PHST- 2023/03/13 00:00 [received]
PHST- 2023/06/09 00:00 [accepted]
PHST- 2023/06/26 06:41 [medline]
PHST- 2023/06/23 01:10 [pubmed]
PHST- 2023/06/22 23:36 [entrez]
PHST- 2023/06/22 00:00 [pmc-release]
AID - 10.1186/s12931-023-02476-5 [pii]
AID - 2476 [pii]
AID - 10.1186/s12931-023-02476-5 [doi]
PST - epublish
SO  - Respir Res. 2023 Jun 22;24(1):166. doi: 10.1186/s12931-023-02476-5.